Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Market Dynamix™ is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the ...
Zacks Investment Research on MSN

Will Keytruda continue to aid Merck's top line in Q4 earnings?

A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...
Medindia

Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO G I), comparing cadonilimab ...
pharmaphorum

Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth

Zymeworks (ZYME) posts strong Phase 3 Ziihera data in HER2+ GEA and eyes up to $440M in milestones plus royalties—read the ...
Managed Healthcare Executive

Study highlights high costs, treatment challenges for older adults with HER2-positive advanced gastric cancer

Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...
The Manila Times

Head-to-Head Real-World Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemot ...